Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

被引：0
|
作者：
Jun Gong
Shant Thomassian
Sungjin Kim
Gillian Gresham
Natalie Moshayedi
Jason Y. Ye
Julianne C. Yang
Jonathan P. Jacobs
Simon Lo
Nick Nissen
Srinivas Gaddam
Mourad Tighiouart
Arsen Osipov
Andrew Hendifar
机构：
[1] Samuel Oschin Comprehensive Cancer Institute,Department of Medicine
[2] Cedars-Sinai Medical Center,The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine
[3] University of California,undefined
来源：
Scientific Reports | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study
    Wainberg, Zev A.
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Macarulla, Teresa
    Mody, Kabir
    Belanger, Bruce
    Maxwell, Fiona
    Moore, Yan
    Thiagalingam, Arunthathi
    Wang, Tiffany
    Zhang, Bin
    Dean, Andrew
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 14 - 24
  • [22] Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience
    Yu, Hung-Yuan
    Lee, Chun-Yang
    Lin, Le-Gin
    Chao, Yee
    Li, Chung-Pin
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (01) : 42 - 50
  • [23] Oxaliplatin, irinotecan, and 5-fluorouracil/leucovorin in advanced gastric adenocarcinoma: A phase II trial
    Comella, P.
    Lorusso, V.
    Maiorino, L.
    Casaretti, R.
    Cannone, M.
    Massidda, B.
    Farris, A.
    Leo, S.
    Roselli, M.
    Sandomenico, C.
    Mancarella, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
    Miki, Masami
    Fujimori, Nao
    Ueda, Keijiro
    Lee, Lingaku
    Murakami, Masatoshi
    Takamatsu, Yu
    Shimokawa, Yuzo
    Niina, Yusuke
    Oono, Takamasa
    Hisano, Terumasa
    Furukawa, Masayuki
    Ogawa, Yoshihiro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [25] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [26] Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.
    Kawaguchi, Yasunori
    Aikawa, Tomomi
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Hosokawa, Ayumu
    Oda, Hisanobu
    Sakai, Tatsunori
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 705 - 705
  • [27] Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyoergy
    Dean, Andrew
    Shan, Yan-Shen
    Jameson, Gayle
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean F.
    Hubner, Richard A.
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi
    Moyo, Victor
    Belanger, Bruce
    Dhindsa, Navreet
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    LANCET, 2016, 387 (10018): : 545 - 557
  • [28] Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
    Desmond Curran
    Carmelo Pozzo
    Jerzy Zaluski
    Magdalena Dank
    Carlo Barone
    Vahur Valvere
    Suayib Yalcin
    Christian Peschel
    Miklós Wenczl
    Erdem Goker
    Roland Bugat
    Quality of Life Research, 2009, 18 : 853 - 861
  • [29] Phase I trial of escalating doses of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients with advanced colorectal cancer (CRC).
    Gravalos, C
    Garcia-Alfonso, P
    Castellanos, D
    Martin, B
    Perez-Manga, G
    Cortes-Funes, H
    Gonzalez-Lama, J
    Paz-Ares, L
    ANNALS OF ONCOLOGY, 2000, 11 : 46 - 46
  • [30] FAFOXIRI: A phase II trial of an alternating regimen of irinotecan/5-fluoruracil/folinic acid and oxaliplatin/5-fluoruracil/folinic acid in metastatic colorectal cancer.
    Ferrari, VD
    Valcamonico, F
    Amoroso, V
    Vassalli, L
    Grisanti, S
    Marpicati, P
    Simoncini, E
    Rangoni, G
    Marini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 285S - 285S
12345